

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 23, 2026**

---

**CANDEL THERAPEUTICS, INC.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-40629**  
(Commission File Number)

**52-2214851**  
(IRS Employer  
Identification No.)

**117 Kendrick St  
Suite 450  
Needham, Massachusetts**  
(Address of Principal Executive Offices)

**02494**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (617) 916-5445**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	CADL	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Candel Therapeutics, Inc., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 23, 2026. As of April 24, 2026, the record date for the Annual Meeting, there were 73,270,239 outstanding shares of the Company’s voting common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2026: (i) to elect four Class II directors, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, to serve until the Company’s 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”).

The Company’s stockholders elected each of the Class II director nominees, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, recommended for election at the Annual Meeting in Proposal 1. The votes cast at the Annual Meeting were as follows:

	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Edward J. Benz, Jr., M.D.	24,897,348	6,796,622	22,175,525
Paul B. Manning	31,591,618	102,352	22,175,525
Maha Radhakrishnan, M.D.	31,047,706	646,264	22,175,525
Paul Peter Tak, M.D., Ph.D., FMedSci	31,414,668	279,302	22,175,525

The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended for ratification in Proposal 2 at the Annual Meeting. The votes cast at the Annual Meeting were as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>
53,543,020	238,508	87,967

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Candel Therapeutics, Inc.

Date: June 24, 2026

By: /s/ Paul Peter Tak  
Paul Peter Tak, M.D., Ph.D., FMedSci  
President and Chief Executive Officer

---

